Sun Pharma Advanced Research Company Limited — Updates, 31-03-2025: Press Release

Sun Pharma Advanced Research Company Ltd. (SPARC) has submitted an Investigational New Drug (IND) application for SBO-154 to the US Food and Drug Administration (FDA). This application signals the intent to begin a global Phase 1 clinical trial targeting advanced solid tumors, following promising results from previous IND-enabling preclinical studies. SBO-154, a novel antibody-drug conjugate (ADC) developed by SPARC, is designed to specifically bind to the MUC1 antigen, releasing a payload that inhibits tumor cell division. This advancement marks a significant milestone for SPARC, as indicated by CEO Anil Raghavan, who highlighted its potential to improve cancer treatment outcomes worldwide. This strategic move could enhance SPARC's position in the biopharmaceutical sector, making it a critical development to watch as they progress toward clinical trials.